





NiCCC SGCTG - NSGO




Trial setting: tumour type/stage	Progressive or recurrent ovarian and endometrial CCC within 6 months of previous platinum
Study Design:	Open Label Randomised Phase II Study
Sponsor:	NHS Greater Glasgow & Clyde
Planned No. of patients:	90 Ovarian and up to 30 endometrial
Current accrual:	65 ovarian patients 8 endometrial patients
Other important information:	Open Sites: UK: 18 France: 20 The Netherlands: 2
Additional Participating Countries:	Due to open: Denmark, Norway, Finland, Spain
Futility analysis performed and IDMC have recommended the trial continue.	



Trial Design



G143 NICCC - Recruitment - Ovarian Patients Only



Primary Endpoint: PFS

Secondary Endpoints: OS, Toxicity, RR, QoL, Q-Twist